These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

205 related articles for article (PubMed ID: 12670777)

  • 1. The inhalers of the future? A review of dry powder devices on the market today.
    Smith IJ; Parry-Billings M
    Pulm Pharmacol Ther; 2003; 16(2):79-95. PubMed ID: 12670777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. What is new in asthma: new dry powder inhalers.
    Hannemann LA
    J Pediatr Health Care; 1999; 13(4):159-65. PubMed ID: 10690079
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, double-dummy, single-dose, efficacy crossover trial comparing formoterol-HFA (pMDI) versus formoterol-DPI (Aerolizer) and placebo (pMDI or Aerolizer) in asthmatic patients.
    Bousquet J; Huchon G; Leclerc V; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():6-12. PubMed ID: 15915007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Evolution of Pressurized Metered-Dose Inhalers from Early to Modern Devices.
    Roche N; Dekhuijzen PN
    J Aerosol Med Pulm Drug Deliv; 2016 Aug; 29(4):311-27. PubMed ID: 26824873
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of co-milling techniques for the production of high dose dry powder inhaler formulation.
    Lau M; Young PM; Traini D
    Drug Dev Ind Pharm; 2017 Aug; 43(8):1229-1238. PubMed ID: 28367654
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A randomized, double-blind, double-dummy, single-dose, crossover trial evaluating the efficacy and safety profiles of two dose levels (12 and 24 microg) of formoterol-HFA (pMDI) vs. those of a dose level (24 microg) of formoterol-DPI (Foradil/Aerolizer) and of placebo (pMDI or Aerolizer) in moderate to severe asthmatic patients.
    Bousquet J; Guenolé E; Duvauchelle T; Vicaut E; Lefrançois G
    Respiration; 2005; 72 Suppl 1():13-9. PubMed ID: 15915008
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metered-dose inhalers, dry powder inhalers, and transitions.
    Fink JB
    Respir Care; 2000 Jun; 45(6):623-35. PubMed ID: 10894455
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The ideal inhaler: design and characteristics to improve outcomes.
    O'Connor BJ
    Respir Med; 2004 Apr; 98 Suppl A():S10-6. PubMed ID: 15139563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. How to achieve good compliance with inhaled asthma therapy.
    Crompton GK
    Respir Med; 2004 Oct; 98 Suppl B():S35-40. PubMed ID: 15481287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Choosing the right inhaler for patients with asthma.
    Newell K; Hume S
    Nurs Stand; 2006 Oct 11-17; 21(5):46-8. PubMed ID: 17061782
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of breath-actuated inhalers in patients with asthma and COPD - an advance in inhalational therapy: a systematic review.
    Salvi S; Gogtay J; Aggarwal B
    Expert Rev Respir Med; 2014 Feb; 8(1):89-99. PubMed ID: 24325614
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Associations between inhaler technique and asthma control among asthma patients using pressurised MDIs and DPIs.
    Basheti IA; Obeidat NM; Ammari WG; Reddel HK
    Int J Tuberc Lung Dis; 2016 May; 20(5):689-95. PubMed ID: 27084826
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A narrative review on the Synchrobreathe™: A novel breath-actuated pressurised metered-dose inhaler for the treatment of obstructive airway diseases.
    Lavorini F; Usmani OS; Salvi S; Rote K; Gaur V; Gogtay J
    Respir Med; 2023; 219():107435. PubMed ID: 38652077
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Double-blind, double-dummy, multinational, multicenter, parallel-group design clinical trial of clinical non-inferiority of formoterol 12 microg/unit dose in a b.i.d. regimen administered via an HFA-propellant-pMDI or a dry powder inhaler in a 12-week treatment period of moderate to severe stable persistent asthma in adult patients.
    Dusser D; Vicaut E; Lefrançois G;
    Respiration; 2005; 72 Suppl 1():20-7. PubMed ID: 15915009
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Metered dose inhalers: current and future uses.
    Levy ML
    Br J Clin Pract Suppl; 1997 May; 89():16-21. PubMed ID: 9519508
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The rejuvenated pressurised metered dose inhaler.
    Bell J; Newman S
    Expert Opin Drug Deliv; 2007 May; 4(3):215-34. PubMed ID: 17489650
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Aerosol devices and asthma therapy.
    Berger W
    Curr Drug Deliv; 2009 Jan; 6(1):38-49. PubMed ID: 19418954
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Importance of inhaler devices in the management of airway disease.
    Virchow JC; Crompton GK; Dal Negro R; Pedersen S; Magnan A; Seidenberg J; Barnes PJ
    Respir Med; 2008 Jan; 102(1):10-9. PubMed ID: 17923402
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Changes in metered dose inhaler propellants].
    Chinet T
    Rev Mal Respir; 2000 Feb; 17(1):15-20. PubMed ID: 10756552
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New delivery systems and propellants.
    Dolovich M
    Can Respir J; 1999; 6(3):290-5. PubMed ID: 10393290
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.